ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For leukemogenesis triggered by BCR-ABL activities, anti-CML treatments with tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, drastically improve survival rates [21–23].